Verizon EVP Kyle Malady sells $48,928 in company stock

Verizon EVP Kyle Malady sold 1,100 shares for $48,928, or $44.48 per share, under a 10b5-1 plan adopted May 18, 2026; he retains 99,966 directly held shares and 20,217 through a 401(k). Verizon shares were cited at $43.37, while InvestingPro estimated fair value at $49.62 and reported a 6.35% dividend yield with 22 consecutive years of dividend increases. Verizon is due to report earnings October 26; KeyBanc expects results generally in line, and the company has settled advertising-related litigation with T-Mobile.

Analysis

The insider sale is weak information: it was pre-planned, small relative to the executive’s disclosed holdings, and should not be treated as a fresh read on Verizon’s outlook. The more relevant near-term risk is the October 26 earnings event. If churn and ARPA improvements translate into durable service-revenue trends, the market may reward execution; if results are merely in line while marketing costs rise, the dividend yield alone may not prevent multiple pressure. The reported fair-value estimate and analyst target are not independent evidence of upside, and the article provides no valuation inputs to validate them.

The advertising dispute’s resolution removes a legal overhang but does not change the underlying carrier-switching contest. For T-Mobile (TMUS), the same competitive mechanism remains: promotional intensity can support subscriber additions while weighing on industry economics. Over 6–18 months, Verizon’s ability to defend retention without escalating discounts matters more than this settlement. The headline’s SpaceX/Tesla framing is unsupported by the body; there is no basis here for a trade in SPCX or TSLA.

Key Decisions for Investors

• No trade on the insider sale. Treat it as routine unless subsequent filings show repeated, discretionary selling or a materially larger reduction in the executive’s holdings.
• Avoid initiating a directional VZ position immediately ahead of earnings based on the article. After October 26, consider a measured long only if churn, ARPA, and service-revenue trends support guidance without materially worse expense commentary; reassess if retention weakens or guidance is cut.
• For a relative-value watchlist, compare VZ with TMUS after results: favor VZ only if it demonstrates retention gains without relying on heavier promotions. The article supplies no comparable valuation or operating data, so this is a catalyst-driven watch, not a current pair recommendation.
• Verify the actual options-implied earnings move, free-cash-flow and dividend coverage, and updated full-year guidance before sizing any position. A sustained deterioration in churn or cash generation would undermine the income thesis; an in-line quarter with stable KPIs may leave limited near-term catalyst.